^
Association details:
| Biomarker: | EGFR mutation + TP53 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) + Ameile (aumolertinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Outcomes in NSCLC Patients with EGFR Co-Mutations Receiving Aumolertinib as First-Line Treatment: the Updated Results
Published date:
08/08/2023
Excerpt:
The median age was 65 years (ranged 32-84), 59.7 % were female, 85.5 % received aumolertinib monotherapy, 14.5 % received aumolertinib combination therapy (bevacizumab or pemetrexed). ORR and DCR in patients receiving aumolertinib monotherapy were 66 % and 96.2 %, respectively...Meanwhile, aumolertinib combination therapy showed superior antitumor activity, ORR and DCR were 88.9 % and 100 %, respectively, and PFS rate at 24 months was 56.3% (Efficacy; Table)...Aumolertinib monotherapy or combination therapy showed excellent and encouraging results in EGFR-mutant NSCLC patients with co-mutations.
Secondary therapy:
pemetrexed
